MedTrace Logo

The Immune Assessment of PD-1 Antibody Therapy in Tumor

NCT06693440 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2024-11-18

No results posted yet for this study

Summary

This retrospective study will leverage previous immune function monitoring results in conjunction with clinical case data at this medical center.

Conditions

  • Efficacy, Team
  • Adverse Event

Interventions

DRUG

PD-1 Inhibitors

Patients received PD-1 inhibitors mono- or combined therapy in real-world clinical practice

Sponsors & Collaborators

  • Quanli Gao

    lead OTHER_GOV

Principal Investigators

  • Quanli Gao · Henan Cancer Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2027-11-13
Completion
2030-11-13

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06693440 on ClinicalTrials.gov